Aurinia Pharmaceuticals (AUPH) Proxy Filing summary

Executive summary

• Focus on commercial execution and restructuring has led to strong business momentum and a debt-free position with over $320M in cash and equivalents.

• Year-over-year growth of 46% in total net revenue and 40% in net product revenue, with LUPKYNIS sales driving consistent growth.

• Expectation to be cash flow positive, excluding share repurchases, in Q2 2024, ahead of prior projections.

• Advancing autoimmune pipeline with Phase 1 clinical program for AUR200, targeting B-cell mediated diseases.

• Forward-looking statements highlight risks and uncertainties, including commercialization challenges and market estimates.

Voting matters and shareholder proposals

• Glass Lewis recommends voting FOR the re-election of all nine incumbent directors.

• Lucien Selce's proposals criticized for lack of transparency, specificity, and credible strategy.

• Selce's background and motives questioned due to past legal issues and vague board nominee plans.

• No alternative director nominees were proposed by Selce during the proxy process.

Board of directors and corporate governance

• Board has added three new directors in the past year, including one appointed in collaboration with a shareholder.

• Directors bring expertise in pharma, biotech, governance, capital markets, and operations.

• Board and management actions are focused on accelerating growth and delivering long-term value.

• ISS recommendations against three directors relate to 2023 say-on-pay, not business performance.